Effect of Alprazolam on the Success of Inferior Alveolar Nerve (IAN) Block

Effect of Preoperative Alprazolam on the Success of Inferior Alveolar Nerve Block for Teeth With Irreversible Pulpitis

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01546090

Enrollment

Registered

2012-03-07

Start date

2011-03-31

Completion date

2012-02-29

Last updated

2012-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inferior Alveolar Nerve Block Failure

Keywords

Alprazolam, benzodiazepines, Inferior alveolar nerve block, irreversible pulpitis, local anesthesia

Brief summary

The purpose of this prospective, randomized, double-blind, placebo-controlled study is to evaluate the effect of preoperative administration of alprazolam on the success of the IAN block for teeth with irreversible pulpitis.

Detailed description

Sixty patients diagnosed with irreversible pulpitis of a mandibular molar randomly receive, in a double-blind manner, identical capsules of either 0.50 mg alprazolam or placebo 45 minutes before the administration of a conventional IAN block. Access is begun 15 minutes after completion of the IAN block, and all patients profound lip numbness. Success is defined as no or mild pain based on visual analog scale recordings during access preparation and initial instrumentation.

Interventions

DRUGAlprazolam

preoperative administration of an orally 0.50 mg single dose

DRUGplacebo

placebo capsules were filled with starch

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* patients with active pain in a mandibular molar * prolonged response to cold testing with Endo-Frost cold spray * Absence of any periapical radiolucency on radiographs * a vital pulp while access cavity preparation * ability to understand the use of pain scales.

Exclusion criteria

* patients were having allergy and sensitivity to benzodiazepines * pregnant and breast feeding patients * patients who had taken sedation within 24 hours before the treatment * having pain in more than one mandibular tooth * unable to give informed consent

Design outcomes

Primary

Measure	Time frame
the success rate of the IAN block	one hour after administration of alprazolam

Secondary

Measure	Time frame
initial pain	one hour after administration of alprazolam

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026